Entering text into the input field will update the search result below

Mr. Feuerstein takes issue with Neuralstem's report of ALS study results

Mar. 12, 2015 12:15 PM ETPalisade Bio, Inc. (PALI) StockBy: Douglas W. House, SA News Editor73 Comments
  • TheStreet's Adam Feuerstein says Neuralstem's (CUR -20.6%) announcement this morning about successful results in a Phase 2 study of NSI-566 in patients with amyotrophic lateral sclerosis (ALS) is a bit too rosy on efficacy.
  • Seven of the 15 patients (47%) in the trial were deemed responders which means, of course, that eight were non-responders (53%). The average ALSFR baseline score was 40 and the average score for the group was 25. The results show that implanting patients with NSI-566 not only failed to improve/maintain muscle function in the overall group, but it continued to deteriorate. He says this is an important distinction because there is no way to pre-select ALS patients who are most likely to respond to treatment with NSI-566. Also, since there was no control arm there is no way to assess the ability of NSI-566 to slow the rate of ALS progression.
  • Investors appear to agree with his take on the data. Shares are down on almost a seven-fold increase in volume.
  • Previously: Phase 2 ALS trial of Neuralstem's NSI-566 meets safety endpoints and shows 47% response rate (March 12)

Recommended For You

About PALI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PALI--
Palisade Bio, Inc.